Non-invasive Prenatal Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Test Type, By Method, By Application, By End User, By Region and Competition, 2020-2030F

Description

The Global Non-invasive Prenatal Testing (NIPT) Market was valued at USD 5.03 billion in 2024 and is projected to reach USD 7.74 billion by 2030, growing at a CAGR of 7.42% during the forecast period. This growth is driven by increased awareness of genetic disorders and the demand for safer, non-invasive prenatal screening alternatives. As maternal age continues to rise globally, so does the risk of chromosomal abnormalities, prompting wider adoption of NIPT as a preferred screening option. The technology offers accurate results using a simple blood sample from the mother, eliminating risks associated with invasive procedures like amniocentesis. Government support for early diagnostic initiatives, advancements in private healthcare access, and the convenience of rapid results further bolster the market. Additionally, innovations such as AI-based analysis and multiplex assay development are broadening the scope and precision of NIPT, while consumer demand for home-based testing solutions is reshaping delivery models to become more patient-centric.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 5.03 Billion
Market Size 2030	USD 7.74 Billion
CAGR 2025-2030	7.42%
Fastest Growing Segment	Trisomy
Largest Market	North America

Key Market Drivers

Rising Maternal Age and Associated Risk of Chromosomal Abnormalities

The trend of delayed motherhood, particularly across Europe, is fueling demand for NIPT. As women increasingly postpone childbirth for career or financial reasons, the average maternal age continues to climb-reaching 30.9 years in England and Wales in 2023, according to the ONS. This age shift is associated with heightened risk for chromosomal anomalies like Down syndrome, Edwards syndrome, and Patau syndrome. NIPT has become the preferred screening method due to its high accuracy, non-invasive nature, and safety for both mother and fetus. The growing maternal population over the age of 35 is particularly inclined to choose NIPT over invasive diagnostic tests. The incorporation of NIPT into public healthcare systems such as the NHS has further increased access, supporting its widespread adoption as part of routine prenatal care.

Key Market Challenges

Limitations of NIPT

Despite its advantages, NIPT faces certain limitations that hinder universal adoption. The possibility of false-positive or false-negative results may lead to unnecessary follow-up procedures or missed diagnoses, undermining patient confidence. Since NIPT is a screening-not diagnostic-tool, positive results must be confirmed through invasive testing methods like amniocentesis or CVS, which may deter some from pursuing initial screening. Additionally, NIPT is largely focused on detecting chromosomal abnormalities and may not identify rare or functional genetic disorders, leaving gaps in comprehensive fetal health assessment. Cost also remains a concern, particularly for patients without insurance coverage or in regions where testing is not publicly funded. The lower sensitivity of NIPT for rare conditions and de novo mutations presents further challenges for families seeking exhaustive genetic insights.

Key Market Trends

Availability of Direct-to-Consumer Tests

The emergence of direct-to-consumer (DTC) NIPT is reshaping the market by expanding accessibility and convenience. These at-home testing options enable individuals to initiate genetic screening without visiting a healthcare provider, promoting early decision-making and broader adoption. DTC models align with the broader movement toward personalized and proactive healthcare, offering users greater control over prenatal care choices. They are especially beneficial for individuals in remote or underserved regions who face barriers to in-clinic services. While concerns over result interpretation and medical oversight remain, the convenience and consumer empowerment offered by DTC NIPT options are expected to drive future demand and innovation within the market.

Key Market Players

YOURGENE HEALTH Plc
Illumina, Inc.
Natera, Inc.
F. Hoffman-La Roche Ltd.
PerkinElmer Inc.
Laboratory Corporation of America Holdings
Eurofins LifeCodexx GmbH
Progenity, Inc.
Genesis Genetics
Quest Diagnostics Incorporated

Report Scope:

In this report, the Global Non-invasive Prenatal Testing (NIPT) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-invasive Prenatal Testing (NIPT) Market, By Product Type:

Consumables
Instruments

Non-invasive Prenatal Testing (NIPT) Market, By Test Type:

Materni 21
Harmony
Panaroma
Verifi
NIFTY
Others

Non-invasive Prenatal Testing (NIPT) Market, By Method:

Ultrasound Detection
Biochemical Screening Testing
Cell-Free DNA Maternal Plasma Tests
Fetal Cells in Maternal Blood Tests
Others

Non-invasive Prenatal Testing (NIPT) Market, By Application:

Trisomy
Microdeletion Syndrome
Others

Non-invasive Prenatal Testing (NIPT) Market, By End User:

Diagnostic Laboratories
Hospitals
Others

Non-invasive Prenatal Testing (NIPT) Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-invasive Prenatal Testing (NIPT) Market.

Available Customizations:

Global Non-invasive Prenatal Testing (NIPT) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-invasive Prenatal Testing (NIPT) Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product Type (Consumables, Instruments)
- 5.2.2. By Test Type (Materni 21, Harmony, Panaroma, Verifi, NIFTY, Others)
- 5.2.3. By Method (Ultrasound Detection, Biochemical Screening Testing, Cell-Free DNA Maternal Plasma Tests, Fetal Cells in Maternal Blood Tests, Others)
- 5.2.4. By Application (Trisomy, Microdeletion Syndrome, Others)
- 5.2.5. By End User (Diagnostic Laboratories, Hospitals, Others)
- 5.2.6. By Region
- 5.2.7. By Company (2024)
5.3. Market Map

6. North America Non-invasive Prenatal Testing (NIPT) Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product Type
- 6.2.2. By Test Type
- 6.2.3. By Method
- 6.2.4. By Application
- 6.2.5. By End User
- 6.2.6. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product Type
    - 6.3.1.2.2. By Test Type
    - 6.3.1.2.3. By Method
    - 6.3.1.2.4. By Application
    - 6.3.1.2.5. By End User
- 6.3.2. Canada Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product Type
    - 6.3.2.2.2. By Test Type
    - 6.3.2.2.3. By Method
    - 6.3.2.2.4. By Application
    - 6.3.2.2.5. By End User
- 6.3.3. Mexico Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product Type
    - 6.3.3.2.2. By Test Type
    - 6.3.3.2.3. By Method
    - 6.3.3.2.4. By Application
    - 6.3.3.2.5. By End User

7. Europe Non-invasive Prenatal Testing (NIPT) Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product Type
- 7.2.2. By Test Type
- 7.2.3. By Method
- 7.2.4. By Application
- 7.2.5. By End User
- 7.2.6. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product Type
    - 7.3.1.2.2. By Test Type
    - 7.3.1.2.3. By Method
    - 7.3.1.2.4. By Application
    - 7.3.1.2.5. By End User
- 7.3.2. United Kingdom Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product Type
    - 7.3.2.2.2. By Test Type
    - 7.3.2.2.3. By Method
    - 7.3.2.2.4. By Application
    - 7.3.2.2.5. By End User
- 7.3.3. Italy Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecasty
    - 7.3.3.2.1. By Product Type
    - 7.3.3.2.2. By Test Type
    - 7.3.3.2.3. By Method
    - 7.3.3.2.4. By Application
    - 7.3.3.2.5. By End User
- 7.3.4. France Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product Type
    - 7.3.4.2.2. By Test Type
    - 7.3.4.2.3. By Method
    - 7.3.4.2.4. By Application
    - 7.3.4.2.5. By End User
- 7.3.5. Spain Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product Type
    - 7.3.5.2.2. By Test Type
    - 7.3.5.2.3. By Method
    - 7.3.5.2.4. By Application
    - 7.3.5.2.5. By End User

8. Asia-Pacific Non-invasive Prenatal Testing (NIPT) Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product Type
- 8.2.2. By Test Type
- 8.2.3. By Method
- 8.2.4. By Application
- 8.2.5. By End User
- 8.2.6. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product Type
    - 8.3.1.2.2. By Test Type
    - 8.3.1.2.3. By Method
    - 8.3.1.2.4. By Application
    - 8.3.1.2.5. By End User
- 8.3.2. India Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product Type
    - 8.3.2.2.2. By Test Type
    - 8.3.2.2.3. By Method
    - 8.3.2.2.4. By Application
    - 8.3.2.2.5. By End User
- 8.3.3. Japan Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product Type
    - 8.3.3.2.2. By Test Type
    - 8.3.3.2.3. By Method
    - 8.3.3.2.4. By Application
    - 8.3.3.2.5. By End User
- 8.3.4. South Korea Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product Type
    - 8.3.4.2.2. By Test Type
    - 8.3.4.2.3. By Method
    - 8.3.4.2.4. By Application
    - 8.3.4.2.5. By End User
- 8.3.5. Australia Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product Type
    - 8.3.5.2.2. By Test Type
    - 8.3.5.2.3. By Method
    - 8.3.5.2.4. By Application
    - 8.3.5.2.5. By End User

9. South America Non-invasive Prenatal Testing (NIPT) Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product Type
- 9.2.2. By Test Type
- 9.2.3. By Method
- 9.2.4. By Application
- 9.2.5. By End User
- 9.2.6. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product Type
    - 9.3.1.2.2. By Test Type
    - 9.3.1.2.3. By Method
    - 9.3.1.2.4. By Application
    - 9.3.1.2.5. By End User
- 9.3.2. Argentina Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product Type
    - 9.3.2.2.2. By Test Type
    - 9.3.2.2.3. By Method
    - 9.3.2.2.4. By Application
    - 9.3.2.2.5. By End User
- 9.3.3. Colombia Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product Type
    - 9.3.3.2.2. By Test Type
    - 9.3.3.2.3. By Method
    - 9.3.3.2.4. By Application
    - 9.3.3.2.5. By End User

10. Middle East and Africa Non-invasive Prenatal Testing (NIPT) Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product Type
- 10.2.2. By Test Type
- 10.2.3. By Method
- 10.2.4. By Application
- 10.2.5. By End User
- 10.2.6. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product Type
    - 10.3.1.2.2. By Test Type
    - 10.3.1.2.3. By Method
    - 10.3.1.2.4. By Application
    - 10.3.1.2.5. By End User
- 10.3.2. Saudi Arabia Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product Type
    - 10.3.2.2.2. By Test Type
    - 10.3.2.2.3. By Method
    - 10.3.2.2.4. By Application
    - 10.3.2.2.5. By End User
- 10.3.3. UAE Non-invasive Prenatal Testing (NIPT) Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product Type
    - 10.3.3.2.2. By Test Type
    - 10.3.3.2.3. By Method
    - 10.3.3.2.4. By Application
    - 10.3.3.2.5. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches

13. Global Non-invasive Prenatal Testing (NIPT) Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. YOURGENE HEALTH Plc
15.2. Illumina, Inc.
15.3. Natera, Inc.
15.4. F.Hoffman La Roche Ltd.
15.5. Perkin Elmer Inc.
15.6. Laboratory Corporation of America Holdings
15.7. Eurofins LifeCodex GmbH
15.8. Progenity, Inc.
15.9. Genesis Genetics
15.10. Quest Diagnostics Incorporated